KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBIT (2016 - 2025)

Historic EBIT for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to -$178.0 million.

  • Novavax's EBIT fell 3283.14% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 20201.25%. This contributed to the annual value of -$248.9 million for FY2024, which is 5605.89% up from last year.
  • Latest data reveals that Novavax reported EBIT of -$178.0 million as of Q3 2025, which was down 3283.14% from $101.1 million recorded in Q2 2025.
  • In the past 5 years, Novavax's EBIT registered a high of $515.5 million during Q1 2025, and its lowest value of -$825.0 million during Q4 2021.
  • Moreover, its 5-year median value for EBIT was -$144.8 million (2024), whereas its average is -$142.5 million.
  • As far as peak fluctuations go, Novavax's EBIT crashed by 193106.24% in 2021, and later skyrocketed by 45594.11% in 2025.
  • Novavax's EBIT (Quarter) stood at -$825.0 million in 2021, then surged by 70.44% to -$243.9 million in 2022, then increased by 24.73% to -$183.6 million in 2023, then rose by 28.59% to -$131.1 million in 2024, then plummeted by 35.81% to -$178.0 million in 2025.
  • Its EBIT was -$178.0 million in Q3 2025, compared to $101.1 million in Q2 2025 and $515.5 million in Q1 2025.